Biophytis S.A. (EPA:ALBPS)
0.0323
-0.0001 (-0.31%)
Mar 13, 2026, 5:35 PM CET
Biophytis Employees
Biophytis had 19 employees as of December 31, 2024. The number of employees decreased by 3 or -13.64% compared to the previous year.
Employees
19
Change (1Y)
-3
Growth (1Y)
-13.64%
Revenue / Employee
n/a
Profits / Employee
€422,632
Market Cap
755.92K
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 19 | -3 | -13.64% |
| Dec 31, 2023 | 22 | -2 | -8.33% |
| Dec 31, 2022 | 24 | -2 | -7.69% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | 4 | 19.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IntegraGen | 40 |
| Aelis Farma | 24 |
| GeNeuro | 17 |
| Plant Advanced Technologies | 16 |
| Oncodesign Precision Medicine Société anonyme | 14 |
| GenSight Biologics | 13 |
| TME Pharma | 12 |
| Aton | 9 |
Biophytis News
- 2 years ago - Biophytis Announces Transfer of ADSs to OTC Market - Accesswire
- 2 years ago - Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program - Accesswire
- 2 years ago - Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity - Accesswire
- 2 years ago - Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities - Accesswire
- 2 years ago - Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) - Accesswire
- 2 years ago - Results of the Combined General Meeting on April 2, 2024 - Accesswire
- 2 years ago - Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia - Accesswire
- 2 years ago - Biophytis Announces Receipt of Nasdaq Notice - Accesswire